Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis.

ABSTRACT: High-dose melphalan (HDM) is the standard conditioning regimen before autologous stem cell transplantation (ASCT) in plasma cell malignancies. Despite prophylactic antiemetics, chemotherapy-induced nausea and vomiting (CINV) remains a prevalent challenge. We retrospectively compared the efficacy of netupitant and palonosetron (NEPA) plus dexamethasone with that of serotonin receptor antagonist (5-HT₃RA)-based regimens (the control group) for patients receiving HDM. The primary endpoint was complete resolution (CR) of CINV in the acute (0-24 hours) and delayed (24-168 hours) phases. Secondary endpoints included overall response rate (ORR), subgroup benefit, and nutritional outcomes. In total, 108 patients were included (NEPA, n = 38; control, n = 70). The NEPA group exhibited hig

SUBMITTER: Cao LQ 

PROVIDER: S-EPMC12911996 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature